Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01440569 |
|
Recruitment Status :
Completed
First Posted : September 26, 2011
Results First Posted : October 28, 2014
Last Update Posted : December 14, 2016
|
Sponsor:
Gilead Sciences
Collaborator:
Janssen Research & Development, LLC
Information provided by (Responsible Party):
Gilead Sciences
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study is to evaluate the safety and tolerability of cobicistat-boosted darunavir plus two fully active nucleoside analogue reverse transcriptase inhibitors in HIV 1 infected, antiretroviral treatment-naive and treatment-experienced adults with no darunavir (DRV) resistance-associated mutations.
After the Week 48 Visit, participants will be given the option to participate in an open-label rollover phase to receive cobicistat and attend visits every 12 weeks until it becomes commercially available, or until Gilead Sciences elects to terminate development of cobicistat.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Acquired Immunodeficiency Syndrome HIV Infections | Drug: COBI Drug: DRV Drug: NRTIs | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 314 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 3b, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir Plus Two Fully Active Nucleoside Reverse Transcriptase Inhibitors in HIV-1 Infected, Antiretroviral Treatment-Naïve and -Experienced Adults With No Darunavir Resistance-associated Mutations |
| Study Start Date : | September 2011 |
| Actual Primary Completion Date : | August 2012 |
| Actual Study Completion Date : | October 2015 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: COBI-boosted DRV
Participants will receive DRV+COBI+2 investigator-selected NRTIs for 48 weeks, and may continue their regimen in the open-label rollover phase.
|
Drug: COBI
150 mg tablet administered orally with food once daily
Other Names:
Drug: DRV 800 mg (2 x 400 mg tablets) administered orally with food once daily
Other Names:
Drug: NRTIs Participants will receive 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs) selected by the investigator after resistance testing at screening and administered according to prescribing information. NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC. |
Primary Outcome Measures :
- Percentage of Participants With Onset of Any Treatment-emergent Grade 3 or 4 Adverse Event Between Baseline and Week 24 [ Time Frame: Up to 24 weeks ]
Secondary Outcome Measures :
- Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 24 (Snapshot Analysis) [ Time Frame: Week 24 ]
- Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48 (Snapshot Analysis) [ Time Frame: Week 48 ]
- Change From Baseline in CD4+ Cell Count at Week 24 [ Time Frame: Baseline; Week 24 ]
- Change From Baseline in CD4+ Cell Count at Week 48 [ Time Frame: Baseline; Week 48 ]
- Percentage of Participants Experiencing Any Treatment-emergent Adverse Event and Any Treatment-emergent Adverse Event Leading to Discontinuation of Study Drug Through Week 24 [ Time Frame: Up to 24 weeks ]
- Percentage of Participants Experiencing Any Treatment-emergent Adverse Event and Any Treatment-emergent Adverse Event Leading to Discontinuation of Study Drug Through Week 48 [ Time Frame: Up to 48 weeks ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adult ≥ 18 years males or non-pregnant females
- Ability to understand and sign a written informed consent form
- General medical condition that does not interfere with the assessments and the completion of the trial
- Treatment Naive: No prior use of any approved or investigational antiretroviral drug for any length of time OR
- Treatment Experienced: Stable antiretroviral regimen for at least 12 weeks prior to screening
- Plasma HIV-1 RNA levels ≥ 1000 copies/mL at Screening
- Screening genotype report shows full sensitivity to two nucleoside analogue reverse transcriptase inhibitors (NRTIs) and no darunavir resistance-associated mutations
- Normal electrocardiogram (ECG)
- Hepatic transaminases ≤ 2.5 × upper limit of normal (ULN)
- Total bilirubin ≤ 1.5 mg/dL
- Adequate hematologic function
- Serum amylase ≤ 2 × ULN and serum lipase ≤ 3 × ULN
- Adequate renal function: Estimated glomerular filtration rate ≥ 80 mL/min
- Females of childbearing potential must agree to utilize protocol-recommended methods of contraception, or be nonheterosexually active, practice sexual abstinence or have a vasectomized partner from Screening throughout the duration of the study period and for 30 days following the last dose of study drug.
- Male subjects must agree to utilize protocol-recommended methods of contraception during heterosexual intercourse from the Screening visit, throughout the duration of the study and for 30 days following discontinuation of investigational medicinal product or be nonheterosexually active, practice sexual abstinence, or be vasectomized.
Exclusion Criteria:
- Previous or current use of darunavir
- A new AIDS-defining condition diagnosed within the 30 days prior to Screening
- Females who are breastfeeding
- Positive serum pregnancy test (if female of childbearing potential)
- Proven or suspected acute hepatitis in the 30 days prior to study entry
- Subjects receiving drug treatment for hepatitis C virus (HCV), or subjects who are anticipated to receive treatment for HCV during the course of the study
- Have a history of ongoing active liver disease or experiencing decompensated cirrhosis irrespective of liver enzyme levels
- Have an implanted defibrillator or pacemaker
- Current alcohol or substance use that may interfere with subject study compliance
- A history of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma
- Active, serious infections requiring parenteral antibiotic or antifungal therapy within 30 days prior to Baseline
- Participation in any other clinical trial
- Any other clinical condition or prior therapy that would make the subject unsuitable for the study or unable to comply with the dosing requirements.
- Subjects receiving ongoing therapy with any of the medications, including drugs not to be used with cobicistat, darunavir, or investigator selected NRTIs; or subjects with any known allergies to cobicistat tablets, darunavir tablets or contraindications for the 2 NRTIs as part of the regimen.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01440569
Locations
Show 49 study locations
Sponsors and Collaborators
Gilead Sciences
Janssen Research & Development, LLC
Investigators
| Study Director: | Marshall Fordyce, MD | Gilead Sciences |
| Responsible Party: | Gilead Sciences |
| ClinicalTrials.gov Identifier: | NCT01440569 |
| Other Study ID Numbers: |
GS-US-216-0130 2011-003501-22 ( EudraCT Number ) |
| First Posted: | September 26, 2011 Key Record Dates |
| Results First Posted: | October 28, 2014 |
| Last Update Posted: | December 14, 2016 |
| Last Verified: | October 2016 |
Keywords provided by Gilead Sciences:
|
HIV-1 HIV Treatment Naïve Treatment Experienced |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Immunologic Deficiency Syndromes Blood-Borne Infections Communicable Diseases Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Immune System Diseases Slow Virus Diseases |
Darunavir Cobicistat HIV Protease Inhibitors Viral Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors |